Century Therapeutics Inc's Comment on Sales, Marketing and Customers
The company is a biotechnology firm developing allogeneic pluripotent stem cell therapies targeting autoimmune diseases, including type 1 diabetes (T1D), and cancer. Their therapeutic programs involve beta islet cells, T cells, and natural killer (NK) cells derived from healthy donors for use in any patient, providing off-the-shelf treatments designed for rapid, reliable delivery at scale to a broad patient population. The company focuses on induced pluripotent stem cells (iPSCs), which have the capacity for indefinite self-renewal and differentiation into any cell type, facilitating extensive genetic editing, reproducibility, and scalable manufacturing. Their platform incorporates iPSC and differentiation expertise alongside CRISPR-mediated precision gene editing to optimize therapeutic cells.
Century Therapeutics Unveils Ambitious Beta Islet Program Aiming to Transform Type 1 Diabetes TreatmentPharmaceutical innovation is often heralded by a blend of promise and peril, especially in a field as complex as diabetes research. On November 13, 2025, Century Therapeutics, Inc., a Philadelphia-based biotechnology firm, took a significant step in this landscape with the announcement of its first dedicated program targeting Type 1 diabetes (T1D). Named CNTY-813, this initiative is notable not merely for its scientific ambition but also for its potential to significantly alter the treatment paradigm for millions suffering from this autoimmune condition.The CNTY-813 programme centres on the development of ...
Century Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company is a biotechnology firm developing allogeneic pluripotent stem cell therapies targeting autoimmune diseases, including type 1 diabetes (T1D), and cancer. Their therapeutic programs involve beta islet cells, T cells, and natural killer (NK) cells derived from healthy donors for use in any patient, providing off-the-shelf treatments designed for rapid, reliable delivery at scale to a broad patient population. The company focuses on induced pluripotent stem cells (iPSCs), which have the capacity for indefinite self-renewal and differentiation into any cell type, facilitating extensive genetic editing, reproducibility, and scalable manufacturing. Their platform incorporates iPSC and differentiation expertise alongside CRISPR-mediated precision gene editing to optimize therapeutic cells.
Sources:
Century Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Century Therapeutics inc’s corporate clients.
For your research, we’ve provided 9 tables on Century Therapeutics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
